Welcome to the 2021 IGCS Meeting Program Scheduling
The meeting will officially run on Central European Time (Rome time-zone, GMT+2)
To convert the meeting times to your local time Click Here
On Demand Hall
ROBOTIC APPROACH FOR A TOTAL HYSTERECTOMY BILATERAL SALPINGO-OOPHORECTOMY AND SUCTION CURETTAGE OF A 20-WEEK SIZE UTERUS WITH GESTATIONAL TROPHOBLASTIC NEOPLASIA. (ID 236)
Abstract
Abstract Body
Introduction:
Gestational trophoblastic neoplasia (GTN) is a malignant trophoblastic disease following either molar or non-molar pregnancies. GTN is primarily treated through uterine evacuation using suction curettage followed by observation or adjuvant chemotherapy based on WHO risk scoring.1,2 In patients who have completed child-bearing, hysterectomy is an acceptable option and may decrease time to remission and required chemotherapy cycles.2
In patients presenting with large volume uterine disease, evidence of metastasis, and high-risk WHO scoring, patients are treated with multi-agent chemotherapy including Etopisode, Methotrexate, Actinomycin-D, Cycophosphamide, and Vincristine (EMA-CA).1,2 EMA-CO has significant risks of complications, including acute hemorrhage and trophoblastic emboli.2,3 In patients with large uteri, surgical risks include uterine perforation and acute hemorrhage,4 requiring a large laparotomic incision. Accordingly, there is a need for risk-reducing minimally invasive approaches in the surgical treatment of GTN.
Description:
The patient is a 53 year old G4P4 presenting with an enlarged uterus of 20 cm with snowstorm appearance, a beta-hCG >400 000IU, lung metastases and a WHO risk score of 8. Preoperatively her blood pressure was 168/105. She underwent a robotic total hysterectomy and bilateral salpingo-oophorectomy, and guided suction curettage. Blood loss was minimal. The patient was scored post-procedure as WHO low risk (3). She received methotrexate, and switched to Actinomycin-D after a plateau in beta-hCG. Her beta-hCG is normal 5 months later.
Conclusion:
We present a minimally invasive approach that ameliorates the surgical and chemotherapy risks of uterine rupture, acute hemorrhage, and trophoblastic emboli, with a normalization of beta-hCGs after treatment with single-agent chemotherapy.